It is a common type of what's called paroxysmal supraventricular tachycardia (PSVT), a cardiac arrhythmia that often affects younger adults with symptoms of dizziness or trouble breathing.

"We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer ...